Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 30, Number 10—October 2024
Dispatch
Dengue Virus Serotype 3 Origins and Genetic Dynamics, Jamaica
Suggested citation for this article
Abstract
We identified 3 clades of dengue virus serotype 3 belonging to genotype III isolated during 2019–2020 in Jamaica by using whole-genome sequencing and phylogenomic and phylogeographic analyses. The viruses likely originated from Asia in 2014. Newly expanded molecular surveillance efforts in Jamaica will guide appropriate public health responses.
An estimated 390 million dengue virus (DENV) infections occur each year worldwide (1), and cases are expected to increase because of vector expansion (2). In the Americas, dengue incidence has increased dramatically since the 1990s (3), yet molecular epidemiologic investigations of DENV have remained uncommon for many countries in the region.
Molecular surveillance of DENV in Jamaica has been limited, and serotype testing has been typically performed only for select samples during epidemics. DENV genomic sequencing has rarely been performed in the Caribbean and almost never in Jamaica; only 1 published study from Jamaica analyzed sequences of patient samples collected in 2007 (4). Jamaica was established as an Abbott Pandemic Defense Coalition site in 2022 (5) and next-generation sequencing (NGS) was introduced in response to the COVID-19 pandemic, so NGS virus surveillance is becoming routine.
In 2019, after a brief lull in dengue cases in the Americas after the introduction of Zika virus (ZIKV) in 2015–2016, a massive surge in dengue cases occurred throughout the region (3,6), at which time Jamaica recorded its greatest number of dengue cases (6). We describe DENV whole-genome NGS results for patients who sought clinical care in Jamaica for dengue during the 2018–2020 epidemic and examine DENV transmission dynamics by using phylogenetics and phylogeography.
We obtained residual diagnostic serum samples positive for DENV nonstructural (NS) protein 1 that were collected from patients at the University Hospital of the West Indies in Kingston, Jamaica, during December 2019–September 2020. Fourteen of 15 total samples were collected during December 2019–January 2020, when cases exceeded the Jamaica Ministry and Health and Wellness’s epidemic threshold; the additional serum sample was collected at the end of the epidemic during September 2020 (7). We extracted total nucleic acids from samples by using the Abbott Diagnostics m2000sp instrument (Abbott, https:/www.abbott.com) and performed virus RNA enrichment by using the Comprehensive Viral Research Panel probe set (Twist Bioscience, https://www.twistbioscience.com).
We obtained 5 whole (100% coverage), 7 near-whole (91%–99% coverage), and 3 partial (28%–65% coverage) genome sequences (Appendix Table 1); all were DENV serotype 3 (DENV-3). We retrieved all DENV-3 sequences available in Nextstrain (https://nextstrain.org) and aligned them with sequences and metadata from this study (https://github.com/LesterJP/Dengue_Jamaica_Study) by using MAFFT (8). We inferred maximum-likelihood phylogenetic reconstructions by using IQ-TREE2 (Appendix). Sequences from Jamaica formed a monophyletic clade within DENV-3 genotype III (GIII), which was further divided into 3 monophyletic subclades: 2 exclusively containing sequences from Jamaica and 1 containing sequences from Jamaica, North America, and Europe (Figure 1, panel A). Those results suggested DENV-3 circulation in Jamaica might have been either from multiple introductions or from endemic evolution that later mirrored the genetics of other DENVs in global circulation. A temporal analysis traced the emergence of DENV-3 to 1960, which had an evolutionary rate of 3.96 × 10−3 substitutions/site/year; DENV-3 GIII was most likely introduced into Jamaica during 2014 (Figure 1, panel B). A Bayesian skygrid reconstruction of the DENV-3 monophyletic clade from Jamaica (Appendix) revealed that genetic diversity remained stable, and the evolutionary rate was 1.78 × 10−3 substitutions/site/year.
We conducted discrete phylogeographic analyses to determine whether DENV-3 genetic diversification in Jamaica arose from external introductions or endemic circulation (Figure 2). Integrating country-specific data with virus dispersal trajectories identified Indonesia as the putative origin of DENV-3 (i.e., the tree root) and showed a clear pattern of intercountry virus spread. A Markov jump reward plot showed the intracountry and intercountry dynamics of DENV-3 globally, indicating China, India, Thailand, and Bangladesh were key virus exporters with high interconnectivity. In the Caribbean, Cuba was a primary source for regional DENV-3 spread and introduction into the United States. For Jamaica specifically, this analysis and the TaxaMarkovJump history reconstruction method (9) indicated 2 major concurrent importation events from Asia; strains from Jamaica were subsequently transmitted to Saint Lucia and other potentially unsampled Caribbean countries. Further intracountry diversification likely led to the 2018–2020 dengue epidemic.
To analyze mutation signatures associated with temporal clades, we extracted strains from Jamaica from the discrete phylogeographic tree and categorized them into temporal groups (TGs) (Figure 3, panel A). Initially (TG1→TG2), amino acid replacements were infrequent and dispersed throughout NS genes. Over time (TG2→TG3), an accumulation of mutations was concentrated in the RNA-dependent RNA polymerase and envelope (E) genes. This trend continued (TG3→TG4) with additional mutations in E and NS2 genes. Mutations in the E gene were located within the lateral ridge and hinge epitopes of strains in TG3 and in the lateral ridge epitope for TG4 (Figure 3, panel B; Figure 4). This pattern of mutations, particularly in the E gene that encodes the most critical protein target of neutralizing antibodies (10), suggests that immune evasion contributed to selection of those mutations. In contrast, we found no indication of immune evasion for E gene domain III (receptor-binding protein) and fusion peptide sequences; those regions were not identified under positive selection.
Episodic and pervasive selection analyses to assess sudden and consistent positive selection were performed to determine which DENV-3 strains and mutations were evolutionarily favored. Branch-site models applied to the complete DENV-3 coding sequence indicated the emergence of each successive time-epoch lineage was under positive, episodic selection (Appendix Table 2). This selection was the predominant force driving retention of numerous mutations within key functional domains for virus replication and structural proteins and determining the evolutionary trajectory of those strains (Figure 3, panel A). We applied site models for the E protein to ascertain which mutations were subject to positive, pervasive selection (Appendix Tables 3, 4) and were likely causes of immune escape. Domain III mutations S666L in TG3 and M582T in TG4 and domain I/II mutation R408K in TG4 strains located at the hinge region were positively selected residues (Figure 3, panel B; Figure 4).
Introductions from Asia most likely brought DENV-3 to Jamaica in 2014, and it was first detected in the country in 2016 (https://www.who.int/emergencies/disease-outbreak-news/item/4-february-2019-dengue-jamaica-en). A mixed outbreak of DENV-3 and DENV-4 infections occurred in 2016 when ZIKV was detected (11). Our findings show that DENV-3 GIII continued to circulate at low levels in Jamaica after 2016, which then led to an explosive DENV-3 GIII disease epidemic during November 2018–March 2020. It remains inconclusive why a period of low-level DENV circulation occurred in the Americas after the introduction of ZIKV in 2015–2016, although ZIKV cross-immunity with DENV and public health interventions and behavioral changes in response to ZIKV might have contributed (3,12).
The E glycoprotein is a critical target of neutralizing antibodies (10). Our findings indicated E glycoprotein mutations were positively selected, underscoring their relevance for adaptive evolutionary responses that might have influenced strain prevalence and virulence. Neutralizing antibodies against E protein domain III of DENV-3 GIII are typically weaker than those against other domains (13), which might explain why domain III mutations were observed over time in our study; subneutralizing antibodies would enable continued virus circulation. Those mutations are not expected to have a large effect on circulation because DENV immunity usually protects from homotypic reinfection; however, breakthrough infections have been described and could contribute to sustained DENV circulation (14).
The circulation of DENV-3 during 2014–2020, a dengue outbreak in 2016, and a large dengue epidemic during 2018–2020 likely produced substantial population immunity to DENV-3 in Jamaica, which might have led to the introduction of a new DENV serotype(s), a well-described risk factor for severe dengue (15). Newly expanded molecular surveillance efforts in Jamaica will enable whole-genome NGS of DENV in clinical samples collected after 2020 to determine ongoing circulation patterns and guide appropriate public health responses.
Ms. Redman is an MSc student in biomedical research at The University of the West Indies, Mona Campus, Jamaica. Her research interests focus on molecular virology, especially arboviruses.
Acknowledgments
Ethics approval for this study was granted through the University of the West Indies Mona Campus Research Committee with yearly extensions (reference code CREC-MN.150 2020/21). Access and use of patient samples was in accordance with policies of the University Hospital of the West Indies.
This work was funded by the National Health Fund Jamaica and Abbott Laboratories.
S.R. is a global infectious diseases scholar who received mentored research training in work leading to the development of this manuscript. This training was supported in part by the University of Buffalo Clinical and Translational Science Institute (award no. UL1TR001412) and the Global Infectious Diseases Research Training Program (award no. D43TW010919).
References
- Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB. Dengue infection. Nat Rev Dis Primers. 2016;2:16055. DOIPubMedGoogle Scholar
- Kraemer MUG, Reiner RC Jr, Brady OJ, Messina JP, Gilbert M, Pigott DM, et al. Publisher Correction: Past and future spread of the arbovirus vectors Aedes aegypti and Aedes albopictus. Nat Microbiol. 2019;4:901. DOIPubMedGoogle Scholar
- Perez F, Llau A, Gutierrez G, Bezerra H, Coelho G, Ault S, et al. The decline of dengue in the Americas in 2017: discussion of multiple hypotheses. Trop Med Int Health. 2019;24:442–53. DOIPubMedGoogle Scholar
- Brown MG, Salas RA, Vickers IE, Heslop OD, Smikle MF. Molecular epidemiology of dengue in Jamaica dengue virus genotypes in Jamaica, 2007. West Indian Med J. 2011;60:120–5.PubMedGoogle Scholar
- Averhoff F, Berg M, Rodgers M, Osmanov S, Luo X, Anderson M, et al. The Abbott Pandemic Defense Coalition: a unique multisector approach adds to global pandemic preparedness efforts. Int J Infect Dis. 2022;117:356–60. DOIPubMedGoogle Scholar
- Lue AM, Richards-Dawson MEH, Gordon-Strachan GM, Kodilinye SM, Dunkley-Thompson JAT, James-Powell TD, et al. Severity and outcomes of dengue in hospitalized Jamaican children in 2018–2019 during an epidemic surge in the Americas. Front Med (Lausanne). 2022;9:
889998 . DOIPubMedGoogle Scholar - Ministry of Health and Wellness, National Epidemiology Unit, Jamaica. Weekly epidemiology bulletin. December 12, 2020 [cited 2024 Jan 19]. https://www.moh.gov.jm/wp-content/uploads/2020/12/Weekly-Bulletin-EW-50_2020-.pdf
- Rozewicki J, Li S, Amada KM, Standley DM, Katoh K. MAFFT-DASH: integrated protein sequence and structural alignment. Nucleic Acids Res. 2019;47(W1):W5–10. DOIPubMedGoogle Scholar
- Hong SL, Lemey P, Suchard MA, Baele G. Bayesian phylogeographic analysis incorporating predictors and individual travel histories in BEAST. Curr Protoc. 2021;1:
e98 . DOIPubMedGoogle Scholar - Gallichotte EN, Baric RS, de Silva AM. The molecular specificity of the human antibody response to dengue virus infections. Adv Exp Med Biol. 2018;1062:63–76. DOIPubMedGoogle Scholar
- Anzinger JJ, Mears CD, Ades AE, Francis K, Phillips Y, Leys YE, et al.; ZIKAction Consortium1,2. ZIKAction Consortium1,2. Antenatal seroprevalence of Zika and chikungunya viruses, Kingston Metropolitan Area, Jamaica, 2017–2019. Emerg Infect Dis. 2022;28:473–5. DOIPubMedGoogle Scholar
- Pan American Health Organization. Response to the epidemic of Zika virus in the Americas [cited 2024 Jan 19]. https://www.paho.org/sites/default/files/2019-04/Zika-Annual-Report-Dec-2015-2016.pdf
- Young E, Carnahan RH, Andrade DV, Kose N, Nargi RS, Fritch EJ, et al. Identification of dengue virus serotype 3 specific antigenic sites targeted by neutralizing human antibodies. Cell Host Microbe. 2020;27:710–724.e7. DOIPubMedGoogle Scholar
- Waggoner JJ, Balmaseda A, Gresh L, Sahoo MK, Montoya M, Wang C, et al. Homotypic dengue virus reinfections in Nicaraguan children. J Infect Dis. 2016;214:986–93. DOIPubMedGoogle Scholar
- Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol. 2013;158:1445–59. DOIPubMedGoogle Scholar
Figures
Suggested citation for this article: Redman SA, Perez LJ, Forberg K, Francis K, Walker JP, Thompson TK, et al. Dengue virus serotype 3 origins and genetic dynamics, Jamaica. Emerg Infect Dis. 2024 Oct [date cited]. https://doi.org/10.3201/eid3010.240170
Original Publication Date: August 27, 2024
1These first authors contributed equally to this article.
Table of Contents – Volume 30, Number 10—October 2024
EID Search Options |
---|
|
|
|
Please use the form below to submit correspondence to the authors or contact them at the following address:
Joshua Anzinger, The University of the West Indies, Ring Road, KGN7, Jamaica
Top